
Join to view full profile
819 sutter aveEast Palo Alto, CA 94303
Phone+1 650-714-4445
Dr. Shreeniwas is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
New York Presbyterian Hospital (Columbia Campus)Fellowship, Critical Care Medicine (Anesthesiology), 1994 - 1995
New York Presbyterian Hospital (Columbia Campus)Fellowship, Pulmonary Disease and Critical Care Medicine, 1992 - 1994
New York Presbyterian Hospital (Columbia Campus)Fellowship, Cardiovascular Disease, 1989 - 1991
UMass Chan Medical SchoolResidency, Internal Medicine, 1986 - 1988
ArMed Forces Medical College PuneClass of 1982
Certifications & Licensure
CA State Medical License 1997 - 2028
NY State Medical License 1989 - 1998
NJ State Medical License 1990 - 1997
American Board of Internal Medicine Internal Medicine
Publications & Presentations
PubMed
- 30 citationsAdhesion Molecules (E-Selectin and ICAM-1) in Pulmonary Allograft RejectionRevati Shreeniwas, Larry L. Schulman, Mangala Narasimhan, Carlton C. McGregor, Charles C. Marboe
Chest. 1996-11-01 - 56 citationsOpportunistic bronchopulmonary infections after lung transplantation: clinical and radiographic findings.Revati Shreeniwas, L. L. Schulman, Y. M. Berkmen, C. C. Mcgregor, John H. M. Austin
Radiology. 1996-08-01 - 287 citationsHypoxic induction of interleukin-8 gene expression in human endothelial cells.M. Karakurum, Revati Shreeniwas, Jing Xian Chen, David J. Pinsky, Shirley ShiDu Yan
The Journal of Clinical Investigation. 1994-04-01
Press Mentions
Bright Minds Begins Subject Dosing in Phase I Dravet Syndrome TrialSeptember 1st, 2022
Dr. Revati Shreeniwas Joins ImmunoMet Therapeutics as Chief Medical OfficerJuly 26th, 2021
Aspen Neuroscience Announces Positive 12‑Month Data from Its ASPIRO Clinical Trial in a Late‑Breaking Oral Presentation at the AD/PDTM 2026 International Conference on Alzheimer’s and Parkinson’s DiseasesMarch 19th, 2026
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









